It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

Eli Lilly’s Acquisition of Adverum Signals Focus on Gene Therapies to Redefine Eye Care

Eli Lilly’s planned acquisition of Adverum Biotechnologies is a...

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)• The Indian Pharmaceutical Market (IPM)...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Marketing

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Policies/Sales

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Strategy

Navigating the Jungle: How to Turn Field Chaos Into Your Brand’s Competitive Advantage

To navigate chaos, you first need to know who...

Cipla appoints Shivam Puri as CEO of One India Business

Shivam Puri has been appointed Chief Executive Officer of...

Mounjaro Upends Semaglutide Gold Rush: IPM May 2026

1. The Eli Lilly & Mounjaro Disruption: A New...

Why Pharma Field Force Fails: The Missing MAP of Motivation

Executive Summary Most healthcare organizations fail at execution, not...

Online Pharmacy:Modest but Accelerating Share of the Retail Pharma Market

India’s pharmaceutical retail landscape remains one of the world’s...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

7 Transitions in Leadership for Indian Pharma Leaders

The rapid pace of change, which began in 2020...

Levamisole Withdrawn in EU: Will India’s Regulator Follow?

On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

The Pharma Professional’s Guide

Brand Building Special Issue with articles on personal branding, brand differentiation and avoiding brand arrogance

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”